Investment & Media

Embark Biotech ApS is an early-stage biotech company focused on developing treatments for metabolic diseases. Our two pipeline programs target adipose tissue and CNS control of energy expenditure and food intake.

We are actively seeking both investors and partnerships to advance our programs and explore new scientific avenues.

You are welcome to reach out to discuss financing and partnering opportunities.

News

EMBARK BIOTECH JOINS BII

September 1st, 2021

Embark Biotech joined the Creation House Program at the BioInnovation Institute with the aim of advancing our lead program, EMB1, through preclinical development. EMB1 is a novel mechanism-of-action for controlling food intake and increasing energy expenditure with potential to treat a wide range of metabolic disorders. In the first half of 2022, we will begin seeking funding opportunities for a series A round to achieve clinical proof-of-concept in genetic forms of obesity. 

EMBARK GETS INNOBOOSTER GRANT

October 15th, 2021

Embark Biotech was awarded an InnoBooster grant from InnovationsFonden to advance the nonclinical development of the EMB1 program.